Nasdaq
$3.63▼ 0.95%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $655.6MShares out 1.800M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
2- 8.6Pre-market26.08.06 21:0310-QEarnings#●●●#●●●
Prime Medicine, Inc.
프라임 메디신(Prime Medicine)은 2026년 6월 30일 기준 분기 보고서(10-Q)를 제출하였으며, 7월 31일 기준 총 181,376,856주의 보통주가 발행되어 있습니다. 현재 만성 육아종성 질환(CGD) 치료제인 PM359의 임상 1/2상 데이터를 바탕으로 FDA로부터 재생의료 첨단치료제(RMAT) 지정을 받아 연구 개발을 진행 중입니다.…more
$3.63-0.95%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.6Pre-market26.08.06 21:028-KKey event
Prime Medicine, Inc.
프라임 메디신은 2026년 2분기 4,210만 달러의 순손실을 기록했으며, 6월 30일 기준 현금 및 투자 자산은 1억 880만 달러로 2027년까지 운영 자금을 확보했습니다. PM577a의 글로벌 임상 1/2상 착수와 PM359의 FDA RMAT 지정 및 2027년 상반기 BLA 제출 추진 등 주요 파이프라인 개발이 진행 중입니다.…more
$3.63-0.95%vs prev closeView filingShare
1 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 21:00#●●●#●●●#●●●
Prime Medicine Doses First Patient in Phase 1/2 Trial for Wilson Disease…more
Prime Medicine has initiated the first patient dosing in its global Phase 1/2 clinical trial for PM577a, a gene-editing therapy for Wilson disease. While the candidate has received FDA Rare Pediatric Disease designation, it remains in early-stage clinical development.…more
$3.63-0.95%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.25Regular26.09.26 02:56
●●●●●●●● ●●●●● ●●●●●●
Prime Medicine has received FDA clearance for its Investigational New Drug application for the AATD therapy PM647. While this allows the company to proceed with clinical trials, the stock price experienced a decline following the announcement.…more
$3.63-0.95%vs prev closeShareBenzinga - 9.25Overnight26.09.25 16:24
●●●●●●●● ●●●●● ●●●●●●
Costco Wholesale reported better-than-expected fourth-quarter earnings and revenue, signaling strong performance. Conversely, Scholastic shares fell after the company missed analyst estimates for both earnings and sales in its first quarter.…more
$3.63-0.95%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report